Federico Cappuzzo

Summary

Affiliation: Istituto Clinico Humanitas
Country: Italy

Publications

  1. ncbi HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer
    Federico Cappuzzo
    N Engl J Med 354:2619-21. 2006
  2. ncbi Should every lung cancer patient be tested for EGFR mutation?
    Federico Cappuzzo
    Expert Opin Ther Targets 10:789-91. 2006
  3. ncbi Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors
    Luca Toschi
    Department of ematology Oncology, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20086 Rozzano, Italy
    Oncologist 12:211-20. 2007
  4. pmc Gemcitabine for the treatment of advanced nonsmall cell lung cancer
    Luca Toschi
    Dana Farber Cancer Institute, Medical Oncology, Boston, MA, USA
    Onco Targets Ther 2:209-17. 2009
  5. doi EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
    Giovanna Finocchiaro
    Istituto Clinico Humanitas IRCCS, Division of Oncology Hematology, Via Manzoni 56, 20089 Rozzano, Italy 39 02 8224 4097 39 02 8224 4590
    Expert Opin Med Diagn 1:183-91. 2007
  6. ncbi Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer
    Federico Cappuzzo
    Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    J Thorac Oncol 2:S12-4. 2007
  7. ncbi EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Federico Cappuzzo
    Department of Hematology Oncology, Istituto Clinico Humanitas, Rozzano, Italy
    J Thorac Oncol 2:423-9. 2007
  8. ncbi Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial
    Federico Cappuzzo
    Department of Hematology Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    J Clin Oncol 25:2248-55. 2007
  9. ncbi EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
    F Cappuzzo
    Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    Ann Oncol 19:717-23. 2008
  10. pmc Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
    F Cappuzzo
    Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Milan University, Rozzano, Italy
    Br J Cancer 99:83-9. 2008

Detail Information

Publications53

  1. ncbi HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer
    Federico Cappuzzo
    N Engl J Med 354:2619-21. 2006
  2. ncbi Should every lung cancer patient be tested for EGFR mutation?
    Federico Cappuzzo
    Expert Opin Ther Targets 10:789-91. 2006
    ..Several studies have recently been completed and these data could indicate the way for a proper selection of patient candidate for TKI therapy...
  3. ncbi Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors
    Luca Toschi
    Department of ematology Oncology, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20086 Rozzano, Italy
    Oncologist 12:211-20. 2007
    ..Several studies have been recently completed, and these data could indicate how to properly select patients who are candidates for TKI therapy...
  4. pmc Gemcitabine for the treatment of advanced nonsmall cell lung cancer
    Luca Toschi
    Dana Farber Cancer Institute, Medical Oncology, Boston, MA, USA
    Onco Targets Ther 2:209-17. 2009
    ....
  5. doi EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
    Giovanna Finocchiaro
    Istituto Clinico Humanitas IRCCS, Division of Oncology Hematology, Via Manzoni 56, 20089 Rozzano, Italy 39 02 8224 4097 39 02 8224 4590
    Expert Opin Med Diagn 1:183-91. 2007
    ..There are several mechanisms that have been identified as responsible for intrinsic or acquired resistance. The aim of the present review is to analyze available data in order to identify an optimal paradigm for patient selection...
  6. ncbi Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer
    Federico Cappuzzo
    Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    J Thorac Oncol 2:S12-4. 2007
  7. ncbi EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
    Federico Cappuzzo
    Department of Hematology Oncology, Istituto Clinico Humanitas, Rozzano, Italy
    J Thorac Oncol 2:423-9. 2007
    ..The aim of this study was to assess whether EGFR and HER2 gene copy number and Akt activation are associated with response to first-line chemotherapy...
  8. ncbi Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial
    Federico Cappuzzo
    Department of Hematology Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    J Clin Oncol 25:2248-55. 2007
    ..The ONCOBELL trial is a prospective phase II study evaluating gefitinib sensitivity in NSCLC patients who never smoked or have increased EGFR gene copy number or activation of the antiapoptotic protein Akt...
  9. ncbi EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
    F Cappuzzo
    Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    Ann Oncol 19:717-23. 2008
    ..Standardized conditions to distinguish subpopulations of colorectal cancer (CRC) patients more and less sensitive to cetuximab therapy remain undefined...
  10. pmc Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
    F Cappuzzo
    Department of Medical Oncology, Istituto Clinico Humanitas IRCCS, Milan University, Rozzano, Italy
    Br J Cancer 99:83-9. 2008
    ..The rarity of MET and IGF1R gene amplification suggests a marginal role in primary resistance. The potential prognostic implication of IGF1R expression merits further evaluation...
  11. pmc MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
    F Cappuzzo
    Department of Oncology Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    Ann Oncol 20:298-304. 2009
    ..MET amplification has been detected in approximately 20% of non-small-cell lung cancer patients (NSCLC) with epidermal growth factor receptor (EGFR) mutations progressing after an initial response to tyrosine kinase inhibitor (TKI) therapy...
  12. ncbi Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges
    F Cappuzzo
    Department of Oncology Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Int J Biol Markers 22:S10-23. 2007
    ....
  13. pmc MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib
    Federico Cappuzzo
    Department of Oncology Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    J Thorac Oncol 4:472-8. 2009
    ....
  14. pmc Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients
    Federico Cappuzzo
    Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico, Department of Oncology Hematology, University of Milan School of Medicine, IRCCS Istituto Clinico Humanitas, Rozzano, Italy
    J Clin Oncol 27:1667-74. 2009
    ..To investigate the prognostic role of genomic gain for MET and epidermal growth factor receptor (EGFR) genes in surgically resected non-small-cell lung cancer (NSCLC)...
  15. ncbi Emerging drugs for small-cell lung cancer
    Giulio Metro
    Istituto Clnico Humanitas, Division of Hematology Oncology, 20089 Rozzano MI, Italy
    Expert Opin Emerg Drugs 14:591-606. 2009
    ....
  16. pmc Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients
    F Cappuzzo
    Department of Oncology Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico IRCCS, Rozzano
    Ann Oncol 21:562-7. 2010
    ..Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections...
  17. ncbi EGFR FISH versus mutation: different tests, different end-points
    Federico Cappuzzo
    Istituto Clinico Humanitas IRCCS, Division of Oncology Hematology, Via Manzoni 56, 20089 Rozzano, Italy
    Lung Cancer 60:160-5. 2008
    ....
  18. doi Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
    Paolo A Zucali
    Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy
    Cancer 112:1555-61. 2008
    ..Gemcitabine and vinorelbine have shown activity in the first-line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine-vinorelbine combination in pemetrexed-pretreated patients with MPM...
  19. ncbi A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial
    Maurizio Infante
    Thoracic Surgery Department, Istituto Clinico Humanitas, Milan, Italy
    Am J Respir Crit Care Med 180:445-53. 2009
    ..Screening for lung cancer with modern imaging technology may decrease lung cancer mortality, but encouraging results have only been obtained in uncontrolled studies...
  20. ncbi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well...
  21. ncbi Impact of biomarkers on non-small cell lung cancer treatment
    Luca Toschi
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Target Oncol 5:5-17. 2010
    ..Relevant clinical issues are represented by the identification of patients who can be reasonably excluded from treatment and by the development of therapeutic approaches able to overcome acquired resistance to anti-EGFR strategies...
  22. ncbi Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study
    Lucio Crino
    Department of Medical Oncology, Perugia Hospital, S Andrea delle Fratte, 06156 Perugia, Italy
    J Clin Oncol 26:4253-60. 2008
    ..This phase II, open-label, parallel-group study compared gefitinib with vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (NSCLC)...
  23. ncbi Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Federico Cappuzzo
    Department of Medical Oncology, Ospedale Civile di Livorno, Livorno, Italy
    Lancet Oncol 11:521-9. 2010
    ....
  24. ncbi Is gemcitabine cost effective in cancer treatment?
    Luca Toschi
    Istituto Clinico Humanitas IRCCS, Department of Onco Hematology, Via Manzoni 56, 20089 Rozzano, Italy
    Expert Rev Pharmacoecon Outcomes Res 7:239-49. 2007
    ..Overall, available data indicate that accurate selection of patients and careful cost analyses should be included in the development of new anticancer drugs for an appropriate use of limited healthcare resources...
  25. ncbi Assessment of tumor response in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Cancer Treat Rev 33:533-41. 2007
    ..New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment...
  26. ncbi Clinical experience with gefitinib: an update
    Federico Cappuzzo
    Bellaria Hospital, Department of Medical Oncology, Bologna, Italy
    Crit Rev Oncol Hematol 58:31-45. 2006
    ..In the present review, we will summarize the results observed in clinical trials with gefitinib. We will present results obtained in NSCLC and in other solid tumor, focusing on biological and clinical markers predicting drug sensitivity...
  27. doi Clinical implications of MET gene copy number in lung cancer
    Luca Toschi
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Future Oncol 6:239-47. 2010
    ..Results from ongoing and future trials will clarify the role of MET TKIs for the treatment of NSCLC and will provide insights into the most appropriate timing for their use...
  28. doi Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology
    Cesare Gridelli
    Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Lung Cancer 76:269-79. 2012
    ..Translational research is essential to identify predictive factors, and should be performed, whenever feasible, in order to achieve treatment optimization with proper patient selection...
  29. doi Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
    Andrea Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    J Clin Pathol 65:218-23. 2012
    ..We therefore assessed EGFR FISH interlaboratory consensus among five molecular diagnostic reference centres...
  30. ncbi Primary pulmonary meningioma: report of a case and review of the literature
    Matteo Incarbone
    Department of Thoracic Surgery, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano Milan, Italy
    Lung Cancer 62:401-7. 2008
    ..When feasible, pulmonary wedge resection by video-assisted thoracic surgery (VATS) including intra-operative histological examination is the most suitable approach to determine the diagnosis and the volume of pulmonary resection...
  31. ncbi Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial
    Maurizio Infante
    Thoracic Surgery Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy
    Lung Cancer 59:355-63. 2008
    ..We herewith present the baseline results of a randomized trial comparing screening for lung cancer with annual spiral computed tomography (CT) versus a yearly clinical review...
  32. pmc Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
    Kimio Yonesaka
    Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Sci Transl Med 3:99ra86. 2011
    ..Moreover, these results suggest that ERBB2 inhibitors, in combination with cetuximab, represent a rational therapeutic strategy that should be assessed in patients with cetuximab-resistant cancers...
  33. pmc Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
    Kurtis D Davies
    Division of Medical Oncology, University of Colorado, MS 8117, 12801 E 17th Ave, Aurora, CO 80045, USA
    Clin Cancer Res 18:4570-9. 2012
    ..In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets...
  34. ncbi Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer
    Vanesa Gregorc
    Department of Oncology, Scientific Institute University Hospital San Raffaele, Milan
    Clin Cancer Res 10:6006-12. 2004
    ....
  35. ncbi Present and future treatment of advanced non-small cell lung cancer
    Lucio Crino
    Division of Medical Oncology, Department of Oncology, Bellaria Hospital, Bologna, Italy
    Semin Oncol 29:9-16. 2002
    ..These should include prevention, screening, and early detection, and the use of novel treatments based on our understanding of the biology and molecular biology of this disease...
  36. ncbi Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
    Federico Cappuzzo
    J Natl Cancer Inst 97:868-9. 2005
  37. ncbi Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients
    Federico Cappuzzo
    University of Colorado Cancer Center, Department of Medicine and Pathology, Aurora, CO 80010, USA
    J Clin Oncol 23:5007-18. 2005
    ..Preclinical data indicate that HER2, a member of the EGFR family, could enhance TKI sensitivity...
  38. ncbi Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Lung Cancer 41:227-31. 2003
    ..We report four cases of Brain Metastases (BM) from non-small cell lung cancer (NSCLC) responding to ZD 1839 therapy after standard therapy failure...
  39. ncbi Gemcitabine in non-small cell lung cancer
    Lucio Crino
    Division of Medical Oncology, Department of Oncology, Bellaria Hospital, Bologna, Italy
    Expert Opin Pharmacother 3:745-53. 2002
    ..Further testing of gemcitabine-based combinations with concurrent radiation is underway...
  40. ncbi Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer
    Rafal Dziadziuszko
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Clin Cancer Res 12:3078-84. 2006
    ....
  41. ncbi New platinum derivatives in advanced non-small cell lung cancer
    Lucio Crino
    Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Suppl Tumori 1:S24-5. 2002
  42. ncbi Perspectives on salvage therapy for non-small-cell lung cancer
    Federico Cappuzzo
    Division of Medical Oncology, Department of Oncology, Bellaria Hospital, Bologna, Italy
    Oncology (Williston Park) 19:989-95; discussion 995-6, 999, 1003-4, passim. 2005
    ..Both drugs have been approved for the treatment of pretreated NSCLC. Other drugs, such as cetuximab (Erbitux) and bevacizumab (Avastin) have shown promising activity in NSCLC and are currently being tested in clinical trials...
  43. ncbi Induction therapy for early-stage non-small-cell lung cancer
    Federico Cappuzzo
    Division of Medical Oncology, Department of Oncology, Bellaria Hospital, Bologna, Italy
    Oncology (Williston Park) 18:32-7. 2004
    ..The results of these ongoing phase III trials should help clarify the role of induction chemotherapy in early-stage disease...
  44. ncbi Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Federico Cappuzzo
    Department of Oncologic Sciences, Bellaria Maggiore Hospital, Bologna, Italy
    J Natl Cancer Inst 96:1133-41. 2004
    ....
  45. ncbi Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)
    Giulio Metro
    Bellaria Hospital Department of Medical Oncology, Via Altura 3, 40139 Bologna Italy
    Rev Recent Clin Trials 1:1-13. 2006
    ..Combination of EGFR targeting agents with other biological drugs is under investigation...
  46. ncbi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Federico Cappuzzo
    University of Colorado Health Sciences Center and University of Colorado Cancer Center, Aurora, CO 80010, USA
    J Natl Cancer Inst 97:643-55. 2005
    ..We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC...
  47. ncbi Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Lung Cancer 42:355-61. 2003
    ....
  48. ncbi Emerging drugs for non-small cell lung cancer
    Federico Cappuzzo
    Division of Medical Oncology, Department of Oncology, Bellaria Hospital, Via Altura 3, 40139, Bologna, Italy
    Expert Opin Emerg Drugs 8:179-92. 2003
    ..Genetic and immunologic therapies represent two additional promising modalities. All of these therapies are in different phases of clinical testing and have shown encouraging activity alone or in combination with chemotherapy drugs...
  49. ncbi Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
    Federico Cappuzzo
    Bellaria Hospital, Division of Medical Oncology, Via Altura 3, 40139 Bologna, Italy
    J Clin Oncol 21:2658-63. 2003
    ..To evaluate the correlation between HER2 expression and gefitinib (ZD 1839, Iressa; AstraZeneca, London, United Kingdom) efficacy in terms of response rate, time to progression (TTP), and overall survival (OS) time...
  50. ncbi Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Cancer 98:128-34. 2003
    ..The objective of this trial was to evaluate the activity and safety of one of the newer platinum-based doublets as a neoadjuvant regimen in patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma (NSCLC)...
  51. ncbi Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:3279-87. 2005
    ..To review recent advances in pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC)...
  52. ncbi Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Oncol 1:S13-9. 2006
    ..Advances in the pathology and computed tomography (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma (BAC) have demonstrated important new prognostic features that have led to changes in classification and diagnostic criteria...
  53. ncbi Medical treatment of brain metastases from lung cancer
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Suppl Tumori 1:S58-9. 2002